The vector of anti-CD22 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD22. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD22 antibody linked to CD28 signaling domains. And the vector product was designed for the treatment of acute lymphoblastic leukemia (ALL) .
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|VP-CAR-LC642||Lenti-CD22 CAR (scFv-CD28-CD3ζ, m971) Viral Particle|
|CAR-T-3-M308-2BZ||Anti-CD22 scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1|
|CAR-T-2-M308-2Z||Anti-CD22 scFv h(CD28-CD3ζ) CART, pCDCAR1|
|CAR-LC065||Anti-CD22 (BL22) h(CD28-41BB-CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC75||Lenti-CD22 CAR (scFv-CD3ζ, FMC63) Viral Particle|
|VP-CAR-LC551||Lenti-CD22 CAR (scFv-CD28-41BB-CD3ζ, HA22) Viral Particle|
|CAR-LC159||Anti-CD22 (m971) h(CD28-41BB-CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC553||Lenti-CD22 CAR (scFv-CD28-CD3ζ, BL22) Viral Particle|
|CAR-T-2-M308-CZ||Anti-CD22 scFv h(b2c-CD3ζ) CART, pCDCAR1|
|VP-CAR-LC81||Lenti-CD22 CAR (scFv-41BB-CD3ζ, FMC63) Viral Particle|
Copyright © 2007 - 2017 Creative Biolabs. All Rights Reserved